| Refine your search: | Drug Interactions |
|
Idamycin PFS
Idamycin PFS is used for: Treating certain types of cancer (eg, acute myeloid leukemia). It is used along with other medicines. It may also be used for other conditions as determined by your doctor.
Consumer Information (MedFacts) · More like this · Add to my drug list
Idamycin PFS
Idarubicin is a cancer (antineoplastic) medication. Idarubicin interferes with the growth of cancer cells and slows their growth and spread in the body. Idarubicin is used to treat a type of blood cancer (acute myeloid leukemia -AML) in adults . Idarubicin may also be used for purposes other than...
Consumer Information (Cerner Multum) · More like this · Add to my drug list
Idamycin PFS
IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi-synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12- Naphthacenedione,...
Professional Monographs (FDA) · More like this · Add to my drug list
Idamycin PFS
Advanced Consumer Information (Micromedex) · More like this
Idarubicin
Idarubicin Pronunciation: (eye-DUH-RUE-bih-sin) Class: Anthracycline Trade Names: Idamycin PFS - Solution for injection 1mg/mL Pharmacology Idarubicin is a DNA-intercalating analog of daunorubicin, which has an inhibitory effect on nucleic...
A-Z Drug Facts (Facts & Comparisons) · More like this · Add to my drug list
See also: Leukemia, Leukocytoclastic Vasculitis, Solid Tumors
Having trouble finding what you want?
- Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
- Try posting your query on the Drugs.com Community Discussion Boards
- Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
- Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
- Image Search is helpful if you want to know what a certain pill looks like.
- News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.
